Adicet Bio, Inc. financial data

Symbol
ACET on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 790% % -31%
Debt-to-equity 21% % 32%
Return On Equity -78% % -45%
Return On Assets -64% % -39%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 153,255,581 shares 86%
Common Stock, Shares, Outstanding 83,253,779 shares 1%
Entity Public Float $84,400,000 USD 10%
Common Stock, Value, Issued $8,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 91,086,464 shares 0.26%
Weighted Average Number of Shares Outstanding, Diluted 91,086,464 shares 0.26%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $97,363,000 USD -3.4%
General and Administrative Expense $23,608,000 USD -15%
Operating Income (Loss) $120,971,000 USD 5.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $115,014,000 USD 2.4%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $115,014,000 USD 2.4%
Earnings Per Share, Basic -1 USD/shares 26%
Earnings Per Share, Diluted -1 USD/shares 26%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $29,099,000 USD -72%
Other Assets, Current $619,000 USD 14%
Assets, Current $106,494,000 USD -48%
Property, Plant and Equipment, Net $17,994,000 USD -25%
Operating Lease, Right-of-Use Asset $11,901,000 USD -21%
Other Assets, Noncurrent $110,000 USD -78%
Assets $140,479,000 USD -43%
Accounts Payable, Current $4,287,000 USD 71%
Employee-related Liabilities, Current $6,166,000 USD 1%
Liabilities, Current $18,941,000 USD -2.3%
Operating Lease, Liability, Noncurrent $11,645,000 USD -22%
Other Liabilities, Noncurrent $125,000 USD 7.8%
Liabilities $31,337,000 USD -9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $56,000 USD -54%
Retained Earnings (Accumulated Deficit) $584,181,000 USD -25%
Stockholders' Equity Attributable to Parent $109,142,000 USD -48%
Liabilities and Equity $140,479,000 USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $25,397,000 USD -11%
Net Cash Provided by (Used in) Financing Activities $104,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $2,861,000 USD -1097%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 83,253,779 shares 1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $28,362,000 USD -132%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $32,002,000 USD -70%
Deferred Tax Assets, Valuation Allowance $119,293,000 USD 20%
Deferred Tax Assets, Gross $122,296,000 USD 19%
Operating Lease, Liability $14,570,000 USD -20%
Depreciation $6,530,000 USD -1.3%
Payments to Acquire Property, Plant, and Equipment $1,492,000 USD 524%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $115,079,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid $17,163,000 USD -22%
Property, Plant and Equipment, Gross $43,909,000 USD 0.29%
Operating Lease, Liability, Current $2,925,000 USD -11%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $2,593,000 USD -32%
Deferred Tax Assets, Operating Loss Carryforwards $74,848,000 USD 14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $26,370,000 USD 43%
Operating Lease, Payments $900,000 USD -40%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $3,003,000 USD -18%
Share-based Payment Arrangement, Expense $12,390,000 USD -47%
Interest Expense $13,000 USD 225%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%